Liver cancer

News

Japan first approval for GSK’s bepirovirsen for CHB

Japan has approved GSK's antisense oligonucleoide Hibsago (bepirovirsen) as a functional cure in chronic hepatitis B virus infection in adult patients

News

Two packets and two vials of different doses of Imfinzi

ASCO26: AZ triplet makes waves in frontline liver cancer

EMERALD-3 suggests a triplet regimen based on AstraZeneca's Imfinzi and Imjudo could be practice-changing as a frontline hepatocellular carcinoma.

News

AZ claims another win for Imfinzi in frontline liver cancer

AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme.

News

AI predicts liver cancer risk with "high accuracy"

A machine learning algorithm could serve as a pre-screen for hepatocellular carcinoma that identifies patients missed by current narrow guidance.

News

MSD, Eisai abandon combination trial in liver cancer

MSD and Eisai's oncology partnership has had mixed fortunes this week, with a disappointment in liver cancer and encouraging data in kidney cancer.

Oncology

Interview at BIO 2025 with Pierre Arséne

Liver cancer diagnostic gets FDA breakthrough status, with P...

Mursla Bio CEO and founder Pierre Arséne discusses the breakthrough designation from the FDA for their blood test to catch liver cancer early.

Japan first approval for GSK’s bepirovirsen for CHB

ASCO26: AZ triplet makes waves in frontline liver cancer

AZ claims another win for Imfinzi in frontline liver cancer

AI predicts liver cancer risk with "high accuracy"

MSD, Eisai abandon combination trial in liver cancer

Liver cancer diagnostic gets FDA breakthrough status, with P...

ESC26: Isomab safety evidence on blood vessel growth for CAD

Discover a new era of healthcare panel engagement: Grounded ...

Liver cancer

Editor's Picks